title: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
authors.affiliation: Benjamin Franklin Hospital, Berlin, Germany.
authors.forename: Hildrun
authors.initials: H
authors.lastname: Haibel
authors.forename: Martin
authors.initials: M
authors.lastname: Rudwaleit
authors.forename: Henning C
authors.initials: HC
authors.lastname: Brandt
authors.forename: Zarho
authors.initials: Z
authors.lastname: Grozdanovic
authors.forename: Joachim
authors.initials: J
authors.lastname: Listing
authors.forename: Hartmut
authors.initials: H
authors.lastname: Kupper
authors.forename: Jürgen
authors.initials: J
authors.lastname: Braun
authors.forename: Joachim
authors.initials: J
authors.lastname: Sieper
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012446:Sacroiliac Joint / Q000187:drug effects / Q000473:pathology; D012720:Severity of Illness Index; D013131:Spine / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab